Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact

News

Jul 15, 2025Blog | Member News, Healthcare

Sanofi acquires Massachusetts biotech Blueprint for $9.1 billion

New England Council member Sanofi, originally a French pharmaceutical and healthcare company, is now a multinational corporation with a significant presence in New England. It recently acquired the Massachusetts-based company, Blueprint Medicines.

This news follows a large sale by Sanofi in late April. Sanofi sold its controlling stake in the consumer health business, Opella, for $11.4 billion. About a month and a half ago, in early June, Sanofi announced the purchase of Blueprint Medicines for $9.1 billion. This acquisition marks a shift for Sanofi, as it continues to move away from its initial focus on cancer therapies and shift toward immunology. This is the company’s biggest acquisition since 2018 with Bioverativ Inc., an offshoot of Biogen Inc.

This “complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions,” said Sanofi’s CEO, Paul Hudson.

The New England Council commends Sanofi for its ongoing commitment to advancing immunology science in the region.

Read more via The Boston Globe

Council Related News
Read Article Blog | Member News, Higher Education

UMass Amherst professor receives NASA grant

Read Article Blog | Member News, Higher Education

UNE introduces five new academic programs to meet workforce demands

Read Article Blog | Council News, Member News, Healthcare

Now Available – Episode 30: Tess Kuenning, President and CEO of the Bi-State Primary Care Association

Read Article Blog | Council News, Healthcare

NEC Supports Bipartisan Cancer Screening Bill

Read Article Blog | Member News, Transportation & Infrastructure

Massport aims to have Logan Airport reach top five status among U.S. mega-airports

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit